Wolff Financial Management LLC Has $4 Million Holdings in Stryker Corporation $SYK

Key Points

• Wolff Financial Management LLC has increased its stake in Stryker Corporation by 12.4%, bringing its total ownership to 10,120 shares valued at approximately $4 million.
• Several institutional investors, including Brighton Jones LLC and Tidal Investments LLC, have markedly increased their stakes in Stryker, which is currently 77.09% owned by such entities.
• Research analysts have a consensus rating of "Moderate Buy" for Stryker, with a target price of $431.42 following multiple upgrades from various financial institutions.

Wolff Financial Management LLC raised its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 12.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,120 shares of the medical technology company's stock after buying an additional 1,113 shares during the quarter. Stryker accounts for approximately 1.0% of Wolff Financial Management LLC's holdings, making the stock its 17th biggest holding. Wolff Financial Management LLC's holdings in Stryker were worth $4,004,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the 4th quarter valued at $26,000. Goodman Advisory Group LLC acquired a new stake in shares of Stryker in the 1st quarter valued at $32,000. City Holding Co. boosted its stake in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares in the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Stryker in the 1st quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday. Evercore ISI upped their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Finally, Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a "hold" rating in a research report on Monday, August 4th. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $430.33.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Trading Down 0.3%

NYSE:SYK traded down $1.23 on Friday, hitting $376.61. 1,924,253 shares of the stock were exchanged, compared to its average volume of 1,391,560. The stock has a market capitalization of $143.98 billion, a price-to-earnings ratio of 49.88, a P/E/G ratio of 2.71 and a beta of 0.93. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company's 50-day moving average price is $387.77 and its 200 day moving average price is $379.28.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio is 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.